These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25151213)

  • 21. Characterization and anti-microbial susceptibility of gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan.
    Saghir S; Faiz M; Saleem M; Younus A; Aziz H
    Indian J Med Microbiol; 2009; 27(4):341-7. PubMed ID: 19736404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotics: action and resistance in gram-negative bacteria.
    Siu LK
    J Microbiol Immunol Infect; 2002 Mar; 35(1):1-11. PubMed ID: 11950113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colonization with antibiotic-resistant Gram-negative bacilli in the neonatal intensive care unit.
    Toltzis P
    Minerva Pediatr; 2003 Oct; 55(5):385-93. PubMed ID: 14608262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic resistance in common pathogens reinforces the need to minimise surgical site infections.
    Dohmen PM
    J Hosp Infect; 2008 Nov; 70 Suppl 2():15-20. PubMed ID: 19022117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Aminoglycosides and polymyxins].
    Molina J; Cordero E; Palomino J; Pachón J
    Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):178-88. PubMed ID: 19303668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empiric antimicrobial therapy for Gram-negative sepsis: back to the future.
    Leekha S; Standiford HC
    Crit Care Med; 2011 Aug; 39(8):1995-6. PubMed ID: 21768802
    [No Abstract]   [Full Text] [Related]  

  • 29. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
    Falagas ME; Bliziotis IA
    Int J Antimicrob Agents; 2007 Jun; 29(6):630-6. PubMed ID: 17306965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.
    Tängdén T
    Ups J Med Sci; 2014 May; 119(2):149-53. PubMed ID: 24666223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy.
    Paterson DL
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S14-20. PubMed ID: 18713045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.
    Vasoo S; Barreto JN; Tosh PK
    Mayo Clin Proc; 2015 Mar; 90(3):395-403. PubMed ID: 25744116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotics in the clinical pipeline in 2011.
    Butler MS; Cooper MA
    J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
    Guervil DJ; Chau T
    Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The spread and acquisition of NDM-1: a multifactorial problem.
    Wailan AM; Paterson DL
    Expert Rev Anti Infect Ther; 2014 Jan; 12(1):91-115. PubMed ID: 24308710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?
    Apisarnthanarak A; Hsu LY; Khawcharoenporn T; Mundy LM
    Expert Rev Anti Infect Ther; 2013 Feb; 11(2):147-57. PubMed ID: 23409821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
    Helfand MS; Bonomo RA
    Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes.
    Gudiol C; Tubau F; Calatayud L; Garcia-Vidal C; Cisnal M; Sánchez-Ortega I; Duarte R; Calvo M; Carratalà J
    J Antimicrob Chemother; 2011 Mar; 66(3):657-63. PubMed ID: 21193475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.
    Chopra I; Schofield C; Everett M; O'Neill A; Miller K; Wilcox M; Frère JM; Dawson M; Czaplewski L; Urleb U; Courvalin P
    Lancet Infect Dis; 2008 Feb; 8(2):133-9. PubMed ID: 18222164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.